This is a list of all content pages that are marked reviewed, but after the review it was subsequently edited. Presumably these pages need to be reviewed again.
11245 reviews are up to date. 204 reviews are stale and are listed below.
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 1
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 1/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 2/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 3
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 3/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 7
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 7/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 8
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 8/Signature 1
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 1
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 2
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 1
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 2
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 3
- Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease/Experiment 1
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease/Experiment 1/Signature 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 1/Signature 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 2
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 2/Signature 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1/Signature 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1/Signature 2
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 2
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 2/Signature 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 3
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 3/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 1/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 2
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 2/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 3
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 3/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 4
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 4/Signature 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1/Signature 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1/Signature 2
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3/Signature 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3/Signature 2
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1/Signature 1
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 7
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 7/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 8
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 8/Signature 1
- Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 1
- Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1/Signature 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1/Signature 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2/Signature 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2/Signature 2
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1/Signature 1
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 1/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5/Signature 2
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1/Signature 1
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1/Signature 2
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 2
- Study 83
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment/Experiment 2
- Body site-typical microbiome signatures for adults
- Body site-typical microbiome signatures for adults/Experiment 1
- Body site-typical microbiome signatures for adults/Experiment 2
- Body site-typical microbiome signatures for adults/Experiment 3
- Body site-typical microbiome signatures for adults/Experiment 4
- Body site-typical microbiome signatures for adults/Experiment 5
- Body site-typical microbiome signatures for adults/Experiment 6
- Body site-typical microbiome signatures for adults/Experiment 7
- Body site-typical microbiome signatures for adults/Experiment 8
- Body site-typical microbiome signatures for adults/Experiment 9
- Body site-typical microbiome signatures for adults/Experiment 10
- Body site-typical microbiome signatures for adults/Experiment 10/Signature 1
- Body site-typical microbiome signatures for adults/Experiment 11
- Body site-typical microbiome signatures for children
- Body site-typical microbiome signatures for children/Experiment 1
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 1
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 2
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 3
- Stachyose ameliorates obesity-related metabolic syndrome via improving intestinal barrier function and remodeling gut microbiota/Experiment 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4/Signature 2
